Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00638196 · ClinicalTrials.gov registry record · Phase 1
Placebo vs. Linoleic Acid Controlled Assessment of Treatment Efficacy in MS
A Phase 1 study, sponsored by University of Rochester.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT00638196 is a Phase 1 study that was terminated before completion, run by University of Rochester. The registered enrollment target is 9 participants.
The verdict
NCT00638196, a Phase 1 study, was terminated before completion, sponsored by University of Rochester.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
Several investigations have suggested that polyunsaturated fatty acids may promote therapeutic effects in MS. This pilot study will determine whether omega-6 polyunsaturated fatty acids (PUFAs),in the form of linoleic acid,can reduce disease activity and prevent disability progression in patients with relapsing MS.This study will seek to measure disease activity as seen on MRI scans in addition to measuring relapse rates.
Interventions
- DRUG Linoleic Acid/Oleic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2008-03 |
| Est. Completion | 2012-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00638196
The ClinicalTrials.gov registry entry for NCT00638196 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Linoleic Acid/Oleic Acid is the first listed.
NCT00638196 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00638196 about?
NCT00638196 is a clinical study titled "Placebo vs. Linoleic Acid Controlled Assessment of Treatment Efficacy in MS". Several investigations have suggested that polyunsaturated fatty acids may promote therapeutic effects in MS. This pilot study will determine whether omega-6 polyunsaturated fatty acids (PUFAs),in the form of linoleic acid,can reduce disease activity and prevent disability progression in patients wi...
What is the current status of trial NCT00638196?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2008-03. Estimated completion is 2012-09.
What interventions are being tested in trial NCT00638196?
The interventions under investigation include: Linoleic Acid/Oleic Acid (DRUG).
Who is sponsoring clinical trial NCT00638196?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.